Ipsen (OTCMKTS:IPSEY) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

Ipsen S.A. (OTCMKTS:IPSEY) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $29.95 and traded as high as $30.56. Ipsen shares last traded at $30.51, with a volume of 1,363 shares changing hands.

Ipsen Stock Down 2.8 %

The stock has a 50 day moving average price of $30.22 and a 200 day moving average price of $29.95.

About Ipsen

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.